Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. - Wikidata - wikimedia - TriplyDB

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.

http://www.wikidata.org/entity/Q33389472

about

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma.Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Advances in the treatment of neutropenia.Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study Risk factors for febrile neutropenia during chemotherapy for HIV-related lymphoma.Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting Epidemiology and outcome of Rhodotorula infection in haematological patients.Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review.Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design.Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study.The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy.Use of risk stratification to guide ambulatory management of neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim.Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma.External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma.Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy.Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases

P2860

Q33752272-DCABAFA6-8627-43C6-B24D-6B69E22D5A95 Q33756369-6B895DD8-923A-4546-B45C-CFFD7C712076 Q33770736-2B2B07BD-38F8-4473-8CD7-1AEFB778981B Q33861071-BDFB693A-514E-4B8F-83DF-07E4B12941E8 Q34026627-1FAA8EAC-E58A-42DB-B86E-A42BA8DBF948 Q34528537-5FA63B33-B64B-4AE1-B5F2-B3AEB132AE16 Q34553998-BA9D6926-149E-41F7-9956-5592E2DC27EE Q34609244-202ACF37-217E-45BE-9382-CE5D2FA46E81 Q35123683-2D957BE5-A52C-44AB-9E2B-F7283726B928 Q35730160-5678E82A-10E9-4BB3-ADC5-671AAFEDBC23 Q35862322-5AE14C3C-BA6C-450B-82FF-9E668AD6B3F5 Q36243957-C400068C-A178-43C5-A255-3A9E0800F27B Q36472941-97D0BB53-4D2B-48A0-B2B4-9DC0DBC5DD63 Q36741541-85DB0BDE-90E6-4F58-9CD1-4E2E7C2F980C Q37718939-ABE956E5-D1E8-4D8D-8EE6-02977AEB0574 Q38037349-20473BF0-B342-4970-A07D-4AE97BDB7849 Q38309710-0D9C2008-6322-486F-9C9D-A3020EFB2C93 Q40163155-AC273126-6CCD-4583-B4F2-09D9DA5B8AD3 Q40180945-C1CA456A-0418-426B-AB9F-A0E72EE78025 Q40222201-DAD84B11-F125-4C1B-BB9F-B2980D8184DF Q40242261-9958A0EC-5EC5-45C7-A5D3-9328C4103103 Q40255259-24BDC68A-154A-4C27-94BE-06CA7266113C Q40335985-63C941BE-549E-409A-AB9C-EFECEAE919AA Q40342442-B84862C8-6C63-47EF-B606-3429ADB104EE Q40410427-9B478E57-824E-41BE-A13C-BCDCDFA75E54 Q41846561-6CEB1EB7-D4B8-4FE7-A467-CAD320A27B0E Q44569718-5E4282F1-44A2-4B2D-B088-8AAD6CDAE64C Q45746480-0D963CEE-A3F3-4BAA-9D51-606B194A48F1 Q46029514-68E82315-D555-4AE7-B540-06D3A26BA25C Q51712236-2C35C866-BE69-49D1-A4F4-0CC18610B714 Q58117321-06A98FBA-D286-47BE-AA99-1421C910F335

P2860

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.

http://www.wikidata.org/entity/Q33389472

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Multivariate analysis of febri ...... al European Neutropenia Study.

@ast

Multivariate analysis of febri ...... al European Neutropenia Study.

@en

type

label

Multivariate analysis of febri ...... al European Neutropenia Study.

@ast

Multivariate analysis of febri ...... al European Neutropenia Study.

@en

prefLabel

Multivariate analysis of febri ...... al European Neutropenia Study.

@ast

Multivariate analysis of febri ...... al European Neutropenia Study.

@en

P1433

Q33389472-74EE0A59-62FE-468F-9CE0-40B6DD2CBFF4

P1476

Q33389472-C7A63F88-EDDC-4BAB-95CD-A8125153271B

P2093

Q33389472-09BB53EF-A28C-4213-BF09-DA7D65207E04

Q33389472-1773348C-560A-43D8-88F7-C2D2C6FB0AEE

Q33389472-63D769A8-F47E-4DAF-B00C-86682901BC5C

Q33389472-66EDA897-7CD2-4742-A0AA-190080C1CD75

Q33389472-8ED64993-8FE3-4FD0-8489-713D27C4ADEC

Q33389472-A53FC1D6-F936-455E-B353-890781358196

Q33389472-B24027F9-B109-4E42-8A0E-0146CC4D9F33

Q33389472-D00B485F-7228-4049-BD1C-75BB3205FDF6

P2860

Q33389472-03B3C734-05BB-4177-B091-1623437AEABC

Q33389472-1364E67B-C6F4-46E5-A1BB-7A46083D529E

Q33389472-13E13997-5AB8-41D4-BAFA-D821C4847FF9

Q33389472-147CFBBB-B78A-47FE-8C69-E3F0271DF89D

Q33389472-21A0AF44-55E2-46ED-A544-7AA4C03B32BF

Q33389472-38F35387-D647-48E5-9C7A-A3AF0237BC69

Q33389472-3D57DE0E-5A23-4FD9-AC46-8D7275ED78BA

Q33389472-4DAAF30F-A364-439C-BB50-8ADE1E4D263F

Q33389472-4FD55F48-51F0-4E5F-BF43-81D8EADBBBDB

Q33389472-6293CBAF-EDCF-49A1-AF37-C6A36CF4225C

P304

Q33389472-C98247A4-EE54-4292-BA09-6353A81EE9A2

P31

Q33389472-5EE5322F-3151-4B55-8E10-6576F070E731

P356

Q33389472-7F99C022-A760-4837-B98F-6A4EB3502377

P407

Q33389472-0A6AE85B-9CEF-4B0D-A11A-CD7E34F994B6

P433

Q33389472-51C91885-316E-41F1-B2E5-41B0BDC0F966

P478

Q33389472-66026A8D-C41A-4AA7-8E24-05B842F4EBE1

P50

Q33389472-7D4AAB28-9776-46E8-B6D2-D986282F57F3

P577

Q33389472-A5F24EE1-DA5D-40B5-AB68-2F26C275D0E4

P5875

Q33389472-4D5D6A1B-6A08-4586-9693-E95F0C060C0F

P698

Q33389472-2BB78F16-0065-4265-80BD-91B476E28F81

P932

Q33389472-6DA809E7-CEF2-445C-AC14-E2A611A481DD

P356

J.1365-2141.2008.07514.X

P1433

British Journal of Haematology

P1476

Multivariate analysis of febri ...... al European Neutropenia Study.

@en

P2093

André Bosly

http://www.w3.org/2001/XMLSchema#string

Christian Jackisch

http://www.w3.org/2001/XMLSchema#string

Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU)

http://www.w3.org/2001/XMLSchema#string

Manuel Constenla

http://www.w3.org/2001/XMLSchema#string

Robert Leonard

http://www.w3.org/2001/XMLSchema#string

Robert Paridaens

http://www.w3.org/2001/XMLSchema#string

Ruth Pettengell

http://www.w3.org/2001/XMLSchema#string

Thomas D Szucs

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.

The colony-stimulating factors: use to prevent and treat neutropenia and its complications.

Risk models for predicting chemotherapy-induced neutropenia.

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.

A critical look at methods for handling missing covariates in epidemiologic regression analyses.

P304

677-685

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2008.07514.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

144

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Schwenkglenks

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23570606

http://www.w3.org/2001/XMLSchema#string

P698

19055662

http://www.w3.org/2001/XMLSchema#string

P932

2680267

http://www.w3.org/2001/XMLSchema#string